Profile data is unavailable for this security.
About the company
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.
- Revenue in USD (TTM)8.41m
- Net income in USD-15.80m
- Incorporated1998
- Employees47.00
- LocationDURECT Corp10240 Bubb RoadCUPERTINO 95014United StatesUSA
- Phone+1 (408) 777-1417
- Fax+1 (408) 777-3577
- Websitehttps://www.durect.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 39.11m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Carisma Therapeutics Inc | 20.71m | -72.50m | 40.71m | 107.00 | -- | 113.09 | -- | 1.97 | -1.78 | -1.78 | 0.5075 | 0.0087 | 0.2153 | -- | -- | 193,551.40 | -75.38 | -30.87 | -91.33 | -34.47 | -- | -- | -350.08 | -255.66 | -- | -- | 0.8322 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Protara Therapeutics Inc | 0.00 | -40.69m | 40.85m | 26.00 | -- | 0.4438 | -- | -- | -3.19 | -3.19 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -41.35 | -37.02 | -43.70 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Singular Genomics Systems Inc | 2.72m | -91.89m | 40.98m | 255.00 | -- | 0.2971 | -- | 15.05 | -37.37 | -37.37 | 1.11 | 55.27 | 0.0108 | 0.2867 | 11.53 | 10,674.51 | -36.46 | -- | -38.85 | -- | -41.11 | -- | -3,375.72 | -- | 8.04 | -- | 0.0696 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| FibroGen Inc | 173.82m | -168.32m | 41.02m | 486.00 | -- | -- | -- | 0.236 | -1.71 | -1.71 | 1.76 | -2.31 | 0.4301 | 1.22 | 44.10 | 357,644.00 | -42.40 | -30.62 | -89.79 | -42.31 | 76.65 | 93.52 | -98.60 | -119.08 | 1.24 | -12.47 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| HST Global Inc | 0.00 | -123.45k | 41.56m | 1.00 | -- | -- | -- | -- | -0.0209 | -0.0209 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -3,300.80 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -27.31 | 5.81 | -- | -- | -- | -0.7858 | -- | -- | -- |
| DURECT Corp | 8.41m | -15.80m | 41.59m | 47.00 | -- | 8.26 | -- | 4.95 | -0.5283 | -0.5283 | 0.2842 | 0.1623 | 0.2143 | 0.682 | 7.26 | 145,017.20 | -40.25 | -37.34 | -208.53 | -53.44 | 80.80 | 91.83 | -187.84 | -139.11 | 0.797 | -38.83 | 0.7135 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Kezar Life Sciences Inc | 7.00m | -98.57m | 41.63m | 58.00 | -- | 0.276 | -- | 5.95 | -1.35 | -1.35 | 0.0962 | 2.07 | 0.0316 | -- | -- | 120,689.70 | -44.47 | -32.54 | -47.84 | -34.09 | -- | -- | -1,408.11 | -4,308.11 | -- | -- | 0.0634 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Passage Bio Inc | 0.00 | -76.57m | 42.06m | 58.00 | -- | 0.4644 | -- | -- | -1.36 | -1.36 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -47.99 | -48.56 | -53.39 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 42.36m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 42.85m | 37.00 | -- | 0.9997 | -- | 5.79 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| vTv Therapeutics Inc | 1.00m | -20.18m | 42.87m | 16.00 | -- | 2.60 | -- | 42.87 | -6.81 | -6.81 | 0.2701 | 5.47 | 0.029 | -- | 6.54 | 62,500.00 | -73.77 | -111.84 | -170.69 | -- | -- | -- | -2,540.90 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -17.75m | 42.95m | 21.00 | -- | 1.39 | -- | -- | -1.65 | -1.65 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -40.79 | -28.83 | -44.71 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -24.41m | 43.40m | 14.00 | -- | -- | -- | -- | -0.2843 | -0.2843 | 0.00 | 0.7193 | 0.00 | -- | -- | 0.00 | -68.77 | -218.20 | -118.93 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Atara Biotherapeutics Inc | 62.39m | -181.05m | 44.12m | 165.00 | -- | -- | -- | 0.7071 | -39.90 | -39.90 | 13.06 | -22.61 | 0.343 | 0.931 | 42.60 | 277,275.60 | -99.55 | -70.20 | -256.98 | -86.94 | 80.14 | -- | -290.20 | -1,559.33 | 0.2945 | -250.76 | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Data as of Sep 23 2024. Currency figures normalised to DURECT Corp's reporting currency: US Dollar USD
19.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ingalls & Snyder LLCas of 30 Jun 2024 | 1.99m | 6.41% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.07m | 3.46% |
| Richmond Brothers, Inc.as of 31 Mar 2024 | 768.34k | 2.48% |
| Gagnon Securities LLCas of 31 Mar 2024 | 380.13k | 1.23% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 339.72k | 1.09% |
| Geode Capital Management LLCas of 30 Jun 2024 | 305.25k | 0.98% |
| Montchanin Asset Management LLCas of 30 Jun 2024 | 301.85k | 0.97% |
| Beirne Wealth Consulting Services LLCas of 31 Mar 2024 | 283.01k | 0.91% |
| Tocqueville Asset Management LPas of 31 Mar 2024 | 256.22k | 0.83% |
| GSA Capital Partners LLPas of 31 Mar 2024 | 241.67k | 0.78% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
